Objective:

To explore the role of PIGL in docetaxel resistance in prostate cancer and identify its regulatory mechanism involving HUWE1, emphasizing its potential as a therapeutic target.

Approach:

Key Findings:

• PIGL mRNA and protein levels are elevated in prostate cancer and correlate with poor prognosis.
• PIGL protein is significantly higher in docetaxel-resistant prostate cancer.
• High PIGL expression promotes proliferation, migration, invasion, and docetaxel resistance in prostate cancer cells.
• HUWE1 is identified as a binding partner of PIGL and acts as its E3 ubiquitin ligase, negatively regulating PIGL protein expression.
• Knockdown of HUWE1 enhances docetaxel resistance, which can be reversed by silencing PIGL.

Interpretation:

The study highlights the critical role of PIGL in prostate cancer progression and docetaxel resistance, with HUWE1 serving as a regulatory factor, suggesting potential therapeutic targets.

Limitations:

• The study primarily relies on in vitro assays, which may not fully replicate in vivo conditions, potentially affecting the applicability of results.
• Further research is needed to validate findings in larger clinical cohorts to ensure robustness.

Conclusion:

PIGL and HUWE1 are significant in the context of docetaxel resistance in prostate cancer, providing insights into potential therapeutic targets.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.